Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients.

ABSTRACT:

Background

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection causes direct lung damage, overwhelming endothelial activation, and inflammatory reaction, leading to acute respiratory failure and multi-organ dysfunction. Ongoing clinical trials are evaluating targeted therapies to hinder this exaggerated inflammatory response. Critically ill coronavirus disease 2019 (COVID-19) patients have shown heterogeneous severity trajectories, suggesting that response to therapies is likely to vary across patients.

Research question

Are critically ill COVID-19 patients biologically and immunologically dissociable based on profiling of currently evaluated therapeutic targets?

Study design and methods

We did a single-center, prospective study in an ICU department

SUBMITTER: Dupont T 

PROVIDER: S-EPMC7831685 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature